Telomir Pharmaceuticals, Inc. 8-K

What Happened
Telomir Pharmaceuticals, Inc. reported on February 5, 2026 (8‑K, Item 8.01) new preclinical cellular data for its lead investigational compound Telomir‑1 (formulated as Telomir‑Zn). In collaboration with Smart Assays Biotechnologies, the company observed a rapid, dose‑dependent intracellular redistribution of metals — increased intracellular zinc with a reciprocal reduction in labile ferrous iron — detectable in ~30 minutes and sustained over a two‑hour window. These changes occurred without loss of cell confluence or viability and are presented as supporting an epigenetic modulation mechanism linked to reduced oxidative stress, improved mitochondrial function, and genomic/epigenetic stability rather than cytotoxic activity.

Key Details

• Filing date: February 5, 2026 (Form 8‑K, Item 8.01).
• Observations: zinc accumulation and reciprocal reduction in labile ferrous iron were dose‑dependent, detected ~30 minutes after exposure, and sustained for ~2 hours.
• Viability: effects observed without loss of cell confluence or viability in the evaluated cellular models.
• Development status: company is finalizing IND‑enabling activities and plans to submit an Investigational New Drug (IND) application in Q1 2026; ongoing/completed preclinical programs include triple‑negative breast cancer and longevity models, and manuscript submissions to peer‑reviewed journals have been initiated.

Why It Matters
For investors, these findings are material because they provide preclinical support for Telomir’s proposed mechanism of action — modulation of intracellular metal balance and epigenetic stability — which the company links to pathways relevant to cancer and age‑related cellular decline. The data are preclinical and not clinical proof of safety or efficacy, but they coincide with the company’s stated near‑term regulatory milestone (IND submission planned in Q1 2026) and ongoing preclinical work that could influence future development timelines and valuation milestones.